Pearl Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
Phase 3
Completed
- Conditions
- COPD
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02268396
- Locations
- 🇺🇸
Pearl Investigative Site, Richmond, Virginia, United States
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
Phase 1
Completed
- Conditions
- COPD
- Interventions
- Drug: PT010 Dose 1Drug: PT010 Dose 2Drug: Placebo MDI
- First Posted Date
- 2014-07-23
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02197975
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
PK Study of PT003 and PT001 in Japanese Healthy Subjects
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02196714
- Locations
- 🇺🇸
SNBL, Baltimore, Maryland, United States
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: BFF MDI 80/9.6 μgDrug: BFF MDI 320/9.6 μgDrug: BFF MDI 160/9.6 μgDrug: FF MDI 9.6 μg
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT02196077
- Locations
- 🇺🇸
Pearl Investigative Site, Spartanburg, South Carolina, United States
Pharmacokinetics and Safety Study of PT010 in Healthy Subjects
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02189304
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: AZD2115 Dose 1Drug: AZD 2115, Dose 2Drug: Placebo MDI
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02109406
- Locations
- 🇺🇸
Pearl Therapeutics Study Site, Spartanburg, South Carolina, United States
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT02105012
- Locations
- 🇺🇸
Pearl Therapeutics Study Site, Everett, Washington, United States
🇺🇸Pearl Therapeutics, Los Angeles, California, United States
Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Inhaled BGF (PT010) Dose 2Drug: Inhaled BGF (PT010) Dose 1Drug: Inhaled BGF (PT010) Dose 3Drug: Inhaled GFF (PT003)Drug: Inhaled Symbicort Dose 1Drug: Inhaled Symbicort Dose 2
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01980615
- Locations
- 🇺🇸
Pearl Therapeutics Study Site, Baltimore, Maryland, United States
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: GP MDI (PT001)Drug: FF MDI (PT005)Drug: GFF MDI (PT 003)
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 892
- Registration Number
- NCT01970878
- Locations
- 🇳🇿
Pearl Investigative Site, Tauranga, New Zealand
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: GP MDIDrug: Placebo MDI
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 2103
- Registration Number
- NCT01854645
- Locations
- 🇳🇿
Pearl Investigative Site, Tauranga, New Zealand
© Copyright 2025. All Rights Reserved by MedPath